Interviews

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, discusses whether sodium glucose co-transporter 1 (SGLT1) inhibitors can yield stroke benefits in patients with type 2 diabetes.

Providers need to put themselves in their patients' shoes and think about how they would like to receive services, emphasized Helen Bygrave, MD, chronic diseases advisor for the Médecins Sans Frontières’ (Doctors Without Borders) Access Campaign.

Gary Lyman, MD, MPH, an oncologist and hematologist, compares the uptake of filgrastim biosimlars with pegfilgrastim biosimilars.

Patients should continue to be monitored while on treatment with SGLT2 inhibitors if they are being treated for comorbid type 2 diabetes and heart failure, emphasized Mikhail N. Kosiborod, MD, cardiologist, vice president of Research at Saint Luke's Health System.

Catlin Dennis, MPH, describes the challenges socially and medically vulnerable youth with diabetes and their families faced during the COVID-19 pandemic.

Ezio Bonifacio, PhD, explains factors associated with childhood type 1 diabetes incidence and why more research is needed among minority populations.

Bobeck Modjtahedi, MD, highlights some of the challenges of using telehealth to treat individuals with diabetic retinopathy.

Adults living with HIV sometimes get lost, and we need to optimize their outcomes, noted Allison Agwu, MD, ScM, FAAP, FIDSA, Johns Hopkins University School of Medicine.

Gary Lyman, MD, MPH, an oncologist and hematologist, gives his thoughts on whether health care institutions need to be doing more to encourage use of biosimilars.

Ann Goebel-Fabbri, PhD, a clinical psychologist in Boston, Massachusettes, discusses how limited research on patients with type 1 diabetes (T1D) and eating disorders hinders progress on developing effective interventions.

Michelle Litchman, PHD, FNP-BC, FAANP, FADCES, an assistant professor at the College of Nursing at the University of Utah, describes the results of a study that looked at diabetes technology use and online peer support systems among Spanish-speaking patients. Findings showed that when these 2 interventions are used in conjunction, a positive feedback loop forms.

On this episode of Managed Care Cast, Charlie Wray, DO, MS, an assistant professor of medicine at the University of California San Francisco, outlines the findings of a paper he coauthored which assessed Americans' experiences with their insurance providers.

After years of having cough related to asthma, it took a long time for a specialist to realize Paulette Nyahay had a chronic cough unrelated to her asthma.

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how biosimilars have fared in the oncology space compared to other therapeutic areas.

Patients with a cough lasting more than 8 weeks are diagnosed with chronic cough, and for a subpopulation of those patients there is no treatable underlying cause of their cough, said Peter Dicpinigaitis, MD, professor of medicine at the Albert Einstein College of Medicine and director of the Montefiore Cough Center.

Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, discusses how the COVID-19 pandemic is likely to impact oncology biosimilar utilization.

Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), outlines why updates were made to the ADA’s Living Standards of Care.

Pediatric patients with atopic dermatitis (AD) often vary in disease severity and it can be difficult to assess how much of a topical therapy is needed, said Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego.

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the benefits of sotagliflozin for individuals with type 2 diabetes and chronic kidney disease or heart failure.

Camillo Ricordi, MD, FNAI, describes the process of islet transplantation and how it can benefit individuals with type 1 diabetes.

Patients with a chronic cough that persists even after treatment usually see a few specialists and have lingering triggers that cause their cough, explained Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

The Supreme Court recently upheld the Affordable Care Act, under which HIV and AIDS are considered preexisting conditions, by a vote of 7 to 2.

Catlin Dennis, MPH, describes her research on the impacts of COVID-19 on Oregon’s most medically and socially vulnerable youth with diabetes.

Leslie Eiland, MD, discusses the benefits of remote monitoring among patients with type 1 diabetes (T1D) living in rural America.

Bobeck Modjtahedi, MD, describes how Kaiser Permanente leveraged its telehealth resources to provide care to those with diabetic retinopathy (DR) throughout the COVID-19 pandemic.

Michelle Litchman, PHD, FNP-BC, FAANP, FADCES, an assistant professor at the College of Nursing at the University of Utah, highlights her research on the benefits of concurrent continuous glucose monitoring and online peer support groups for Spanish-speaking patients with diabetes.

Aleksandar Kostic, PhD, an assistant professor of microbiology at Harvard Medical School, describes the research linking gut microbiota and incidence of type 1 diabetes.

Ezio Bonifacio, PhD, discusses the optimal time to begin monitoring for type 1 diabetes (T1D) in children genetically at risk for the disease.